These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 33987813)

  • 21. Clinical neurogenetics: amyotrophic lateral sclerosis.
    Harms MB; Baloh RH
    Neurol Clin; 2013 Nov; 31(4):929-50. PubMed ID: 24176417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated peripheral levels of receptor-interacting protein kinase 1 (RIPK1) and IL-8 as biomarkers of human amyotrophic lateral sclerosis.
    Wei J; Li M; Ye Z; Hu X; He X; Wang J; Chen G; Zou C; Xu D; Zhang H; Yuan J; Zha Y
    Signal Transduct Target Ther; 2023 Dec; 8(1):451. PubMed ID: 38086800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The potential role of glycogen synthase kinase 3 inhibitors as amyotrophic lateral sclerosis pharmacological therapy.
    Palomo V; Perez DI; Gil C; Martinez A
    Curr Med Chem; 2011; 18(20):3028-34. PubMed ID: 21651477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory checkpoints in amyotrophic lateral sclerosis: From biomarkers to therapeutic targets.
    Jiang Z; Wang Z; Wei X; Yu XF
    Front Immunol; 2022; 13():1059994. PubMed ID: 36618399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting Abnormal Nrf2/HO-1 Signaling in Amyotrophic Lateral Sclerosis: Current Insights on Drug Targets and Influences on Neurological Disorders.
    Minj E; Yadav RK; Mehan S
    Curr Mol Med; 2021; 21(8):630-644. PubMed ID: 33430731
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A molecular view of amyotrophic lateral sclerosis through the lens of interaction network modules.
    Jensen KH; Stalder AK; Wernersson R; Roloff-Handschin TC; Hansen DH; Groenen PMA
    PLoS One; 2022; 17(5):e0268159. PubMed ID: 35576218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Repurposing carbamazepine for the treatment of amyotrophic lateral sclerosis in SOD1-G93A mouse model.
    Zhang JJ; Zhou QM; Chen S; Le WD
    CNS Neurosci Ther; 2018 Dec; 24(12):1163-1174. PubMed ID: 29656576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Purinergic P2X
    Mckenzie ADJ; Garrett TR; Werry EL; Kassiou M
    ACS Chem Neurosci; 2022 May; 13(10):1479-1490. PubMed ID: 35512313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induced pluripotent stem cells-based disease modeling, drug screening, clinical trials, and reverse translational research for amyotrophic lateral sclerosis.
    Okano H; Morimoto S; Kato C; Nakahara J; Takahashi S
    J Neurochem; 2023 Dec; 167(5):603-614. PubMed ID: 37952981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Scler osis (ALS) as Neurodegenerative Diseases and their Treatments: A Review Study.
    Deeb O; Nabulsi M
    Curr Top Med Chem; 2020; 20(26):2391-2403. PubMed ID: 32972341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a Mendelian randomization study.
    Li Z; Tian M; Jia H; Li X; Liu Q; Zhou X; Li R; Dong H; Liu Y
    Amyotroph Lateral Scler Frontotemporal Degener; 2024 Feb; 25(1-2):197-206. PubMed ID: 37688479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches.
    Kukharsky MS; Skvortsova VI; Bachurin SO; Buchman VL
    Med Res Rev; 2021 Sep; 41(5):2804-2822. PubMed ID: 32815157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol.
    Kalmar B; Lu CH; Greensmith L
    Pharmacol Ther; 2014 Jan; 141(1):40-54. PubMed ID: 23978556
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small molecules targeting different cellular pathologies for the treatment of amyotrophic lateral sclerosis.
    Elmansy MF; Reidl CT; Rahaman M; Özdinler PH; Silverman RB
    Med Res Rev; 2023 Nov; 43(6):2260-2302. PubMed ID: 37243319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using Drugs as Molecular Probes: A Computational Chemical Biology Approach in Neurodegenerative Diseases.
    Emon MA; Kodamullil AT; Karki R; Younesi E; Hofmann-Apitius M
    J Alzheimers Dis; 2017; 56(2):677-686. PubMed ID: 28035920
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New insights into the gene expression associated to amyotrophic lateral sclerosis.
    Recabarren-Leiva D; Alarcón M
    Life Sci; 2018 Jan; 193():110-123. PubMed ID: 29241710
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic determinants of amyotrophic lateral sclerosis as therapeutic targets.
    Bosco DA; Landers JE
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):779-90. PubMed ID: 20942785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histamine beyond its effects on allergy: Potential therapeutic benefits for the treatment of Amyotrophic Lateral Sclerosis (ALS).
    Volonté C; Apolloni S; Sabatelli M
    Pharmacol Ther; 2019 Oct; 202():120-131. PubMed ID: 31233766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Research on Traditional Chinese Medicine compounds and their preparations for Amyotrophic Lateral Sclerosis.
    Zhu J; Shen L; Lin X; Hong Y; Feng Y
    Biomed Pharmacother; 2017 Dec; 96():854-864. PubMed ID: 29078263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Explore the pharmacological basis of ShengJiYiSui decoction in the treatment of amyotrophic lateral sclerosis based on network pharmacology and molecular docking technology.
    Luo S; Yang L; Ma B; Wang X; Lu Y; Ma S; Wang D; Qu H; Zou L
    Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(13):156-161. PubMed ID: 38158673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.